Avastin Phase III Trial Meets Endpoint: PFS in Platinum-Sensitive Ovarian Cancer
Iniparib Doesn’t Meet Survival, PFS Endpoints In Phase III Trial in Triple-Negative Breast Cancer
Sentinel Node Disection No Worse Than Axillary
Triple-Negative Breast Cancer Equally Aggressive in Whites
RG7204 Meets Endpoints Of Extending Survival, PFS
INSPIRE Enrollment Stopped; Thromboembolism Risk Cited
Tarceva Reaches Endpoint Early: Longer PFS Than Chemo Alone
mTOR Inhibitor Improves PFS In Metastatic Sarcoma Patients
Afinitor Tablet Doubles PFS; Lowers Progression Risk 65%
Study Links Native American Ancestry to Leukemia Relapse
Study Explores Reasons Women Avoid Mammograms
Hormone Therapy At Menopause Linked to More Breast Cancer Risk
Children of Male Cancer Survivors Have Highrt Risk of Birth Defects
Study Finds No Link Between Tumor Grade and Relapse Risk
Clinical Trials Approved By NCI CTEP Last Month
Rituxan Approved as Maintenance For Advanced Follicular Lymphoma
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- At AACR, Letai announces prevention and screening project for southern Appalachia, describes a future without paylines
There’s “clear evidence that funding is moving and the system is working.” - CBER Director Vinay Prasad dared to “say no to drugs”
- Mayo Clinic AI detects pancreatic cancer up to three years before diagnosis, validation study finds
- Forty years after Chernobyl: Little evidence to show that radiation released from the accident increased cancers globally
- Kennedy hints at intended USPSTF reforms at Senate Finance Committee hearing
